Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Last trade$18.31
Day change+$4.55 (+33.07%)
Day range$13.49 – $18.99
Volume977,534
Market cap$202M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$201.97M
Price / earnings
—
Price / book
64.8×
Price / sales
—
EV / sales
—
EV / EBITDA
-8.83×
Profitability
Earnings per share
-$1.48
Return on assets
-244.25%
Return on equity
-695.56%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.54×
Quick ratio
1.54×
Cash ratio
1.54×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.49M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GLSI, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$462.93K
$518.19K
$355.19K
$653.07K
$352.84K
$497.6K
$1.02M
$437.01K
Research and development
$3.56M
$5.21M
$7.59M
$3.52M
$3.42M
$2.27M
$8.69M
$2.29M
Total operating expenses
$4.02M
$5.73M
$7.94M
$4.17M
$3.77M
$2.77M
$9.71M
$2.73M
Operating income
-$4.02M
-$5.73M
-$7.94M
-$4.17M
-$3.77M
-$2.77M
-$9.71M
-$2.73M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$3.95M
-$5.66M
-$7.92M
-$4.15M
-$3.75M
-$2.74M
-$9.67M
-$2.67M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$3.95M
-$5.66M
-$7.92M
-$4.15M
-$3.75M
-$2.74M
-$9.67M
-$2.67M
Net income attributable to common shareholders
-$3.95M
-$5.66M
-$7.92M
-$4.15M
-$3.75M
-$2.74M
-$9.67M
-$2.67M
EBITDA
-$4.02M
-$5.73M
-$7.94M
-$4.17M
-$3.77M
-$2.77M
-$9.71M
-$2.73M
Basic earnings per share
-$0.27
-$0.39
-$0.57
-$0.30
-$0.28
-$0.21
-$0.74
-$0.20
Diluted earnings per share
-$0.27
-$0.39
-$0.57
-$0.30
-$0.28
-$0.21
-$0.74
-$0.20
Recent news
Company coverage with links to the original publishers.
Greenwich LifeSciences announced that two abstracts on its Phase III FLAMINGO-01 clinical trial evaluating GLSI-100 immunotherapy for breast cancer recurrence prevention have been accepted for presentation at the San Antonio Breast Cancer Symposium 2026. The company will present two posters on December 9, 2026, authored by the FLAMINGO-01 Steering Committee.
Greenwich LifeSciences reported delays in filing its Form 10-K for fiscal year 2025 due to coordination issues between dual auditors regarding accounts payable adjustments related to its Phase III FLAMINGO-01 clinical trial. The company maintains a cash balance of approximately $10.5 million as of March 31, 2026, and reported preliminary positive data from the trial showing a 70-80% reduction in breast cancer recurrence rates in the non-HLA-A*02 patient arm.
Greenwich LifeSciences announced that an abstract presenting preliminary data from its Phase III FLAMINGO-01 trial of GLSI-100 immunotherapy has been accepted for presentation at the 2026 ASCO Annual Meeting (May 28-June 2). The non-HLA-A*02 open-label arm, now fully enrolled with 250 patients, shows approximately 70-80% reduction in breast cancer recurrence rates after the Primary Immunization Series, consistent with Phase IIb results. The company plans to attend multiple oncology conferences in coming months.
Greenwich LifeSciences received a notification from Nasdaq on April 16, 2026, indicating non-compliance with listing rules due to failure to timely file its Annual Report on Form 10-K for fiscal year 2025. The company's stock continues to trade on Nasdaq Capital Market under ticker GLSI with no immediate effect on listing status. The company is working with auditors to file the report as soon as possible.
Greenwich LifeSciences presented preliminary immune response data from the Phase III FLAMINGO-01 trial of GLSI-100, an immunotherapy for breast cancer recurrence prevention. The non-HLA-A*02 open label arm (247 patients) showed a statistically significant 4-fold increase in delayed-type-hypersensitivity (DTH) immune reactions from 5.2% at baseline to 20.4% at months 4-6 (p<0.001). Preliminary recurrence rate analysis showed approximately 70-80% reduction in recurrence rates after the primary immunization series, supporting the drug's mechanism of action. Over 1,300 patients have been screened for the trial to date.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.